Given our specific interest in PDA, we also tested drug impact on a newly generated, C57BL/6-based tumor line PDA30364, which was established from a tumor that arose in a genetically engineered PDA model driven by KRAS-G12D and P53-R172H. This evidence concerns the gene TP53 and Patent ductus arteriosus.